Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model

• Main Authors: Daniel Morales-Cano (Author), Jose Luis Izquierdo-García (Author), Bianca Barreira (Author), Sergio Esquivel-Ruiz (Author), Maria Callejo (Author), Rachele Pandolfi (Author), Palmira Villa-Valverde (Author), Ignacio Rodríguez (Author), Angel Cogolludo (Author), Jesus Ruiz-Cabello (Author), Francisco Perez-Vizcaino (Author), Laura Moreno (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Despite increasing evidence suggesting that pulmonary arterial hypertension (PAH) is a complex disease involving vasoconstriction, thrombosis, inflammation, metabolic dysregulation and vascular proliferation, all the drugs approved for PAH mainly act as vasodilating agents. Since excessi...